Biomarkers for immunotherapy in esophageal cancer

The development of immunotherapy, especially immune-checkpoint inhibitors targeting PD-1/PD-L1, has improved the outcomes of patients with esophageal cancer. However, not all population derives benefit from the agents. Recently, kinds of biomarkers were introduced to predict the response to immunoth...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2023-05, Vol.14, p.1117523-1117523
Main Authors: Wang, Xuelian, Wang, Ping, Huang, Xiang, Han, Yanan, Zhang, Pei
Format: Article
Language:English
Subjects:
biomarker
Biomarkers, Tumor
cancer immunity
Carcinoma, Non-Small-Cell Lung - drug therapy
esophageal cancer
Esophageal Neoplasms - therapy
Humans
Immunology
Immunotherapy
Lung Neoplasms - drug therapy
PD-1/PD-L1
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The development of immunotherapy, especially immune-checkpoint inhibitors targeting PD-1/PD-L1, has improved the outcomes of patients with esophageal cancer. However, not all population derives benefit from the agents. Recently, kinds of biomarkers were introduced to predict the response to immunotherapy. However, the effects of these reported biomarkers are controversial and many challenges remain. In this review, we aim to summarize the current clinical evidence and provide a comprehensive understanding of the reported biomarkers. We also discuss the limits of the present biomarkers and propose our own opinions on which viewers' discretion are advised.
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2023.1117523